Company

We’re using our inflammatory mechanisms and immune system knowledge to redefine respiratory medicine and target lung, liver and kidney disease.

We’re expanding rapidly beyond our focus in blood and gynaecological cancers into lung and gastrointestinal cancers, prostate cancers, and other solid tumours.

We’re leaders in HIV, focused on ending the global epidemic. We have an industry-leading pipeline driven by patient insights.

Our priorities include seasonal and chronic infections, common childhood diseases, and critical conditions like meningitis. We also focus on bacterial infections where resistance creates an urgent need for new treatments.